Form 4: Alumis Director Zhengbin Yao Granted 49,800 Stock Options

Alumis Inc. director Zhengbin Yao was granted 49,800 stock options with an exercise price of $4.10, vesting over time and upon specific corporate events.

Summary

• Zhengbin Yao, a Director at Alumis Inc., was granted 49,800 stock options.
• The options have an exercise price of $4.10 per share.
• The grant date for these options was July 30, 2025.
• The options expire on July 29, 2035.
• The shares underlying the option will vest on the first anniversary of the grant date (July 30, 2026).
• Full vesting will occur on the date of Alumis Inc.'s 2026 annual stockholder meeting, contingent on Mr. Yao's continuous service.
• The options will also fully vest upon a Change in Control, subject to continuous service.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating alignment of interests and retention efforts. It's a standard compensation practice, not indicative of extraordinary positive or negative news, hence a neutral-to-positive score.

Positives

• Grant of stock options to a director aligns management incentives with shareholder interests.
• The vesting schedule encourages long-term commitment from the director.
• The full vesting upon a Change in Control provides an incentive for strategic transactions that could benefit shareholders.

Negatives

• No immediate cash inflow for the director from the grant itself, as it's an option, not a stock award.
• The value of the options is dependent on the future stock price exceeding the exercise price of $4.10.

Risks

• The value of the stock options is subject to market fluctuations and the company's performance.
• If the stock price does not exceed the exercise price of $4.10, the options may expire worthless.
• Vesting is contingent on continuous service, meaning the director must remain with the company to realize the full benefit.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the vesting schedule and expiration date of the granted options.

Industry Context

This Form 4 filing reports a standard equity compensation grant to a director, a common practice across industries to align executive and director interests with shareholder value. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• The grant of stock options to a director is a common form of executive and director compensation, aligning their interests with long-term shareholder value.
• The specific number of options (49,800) and the exercise price ($4.10) would typically be evaluated against peer companies in the biotechnology or pharmaceutical sector, considering Alumis Inc.'s market capitalization, stage of development, and overall compensation philosophy.
• Without specific peer compensation data, a direct comparison to industry benchmarks for similar roles at companies like Moderna, BioNTech, or other clinical-stage biotech firms is not possible from this filing alone, but the mechanism itself is standard.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial interests with the company's stock performance, potentially benefiting shareholders if the stock price increases.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The shares underlying the options will vest on the first anniversary of the grant date (July 30, 2026).
• Full vesting will occur on the date of the Issuer's 2026 annual stockholder meeting, subject to continuous service.
• The options will expire on July 29, 2035, if not exercised.

Key Dates

Recommendation

This Form 4 filing reports a routine stock option grant to a director, which is a standard compensation practice. It does not contain information that would fundamentally alter the investment thesis for Alumis Inc. While it aligns the director's interests with shareholders, it does not provide new financial performance data, strategic shifts, or material news that would warrant a 'buy' or 'sell' recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate as it maintains the current position without new compelling reasons to change it.

Keywords

Alumis Inc., ALMS, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Incentive Plan, Zhengbin Yao